Key takeaways from the landmark S1826 trial

A Phase III trial, termed S1826, has demonstrated practice-changing results for advanced Hodgkin lymphoma patients. The trial took an exceptional approach by combining young and older patients into one study, giving them the exact same treatments. In this exclusive interview we speak with Jonathan Friedberg (Wilmot Cancer Institute Director at the University of Rochester, NY, USA), who is leading the study, to uncover more about the clinical trial design and what the next steps are. What are the key takeaways from the S1826 clinical trial for advanced Hodgkin lymphoma patients? The trial showed that nivolumab with doxorubicin, vinblastine, and dacarbazine...